Trial Profile
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Evofosfamide (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Threshold Pharmaceuticals
- 04 Jun 2018 Results of comparison of pharmacokinetic data from MAESTRO trial to that of a phase II (404 study) were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, according to a Molecular Templates media release.
- 16 May 2018 According to a Molecular Templates media release, interim results will be presented at t the American Society of Clinical Oncology (ASCO) Annual Meeting 2018.
- 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.